stockportfolio.pro
Stocks / MRVI vs VCEL
MRVI vs VCEL
Maravai LifeSciences Holdings, Inc. and Vericel Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Maravai LifeSciences Holdings, Inc. (MRVI) | Vericel Corporation (VCEL) | |
|---|---|---|
| Market cap | $1.9B | $1.9B |
| Revenue (latest FY) | $185.74M | $276.26M |
| Net income (latest FY) | $-130.77M | $16.52M |
| Revenue growth (5y CAGR) | -8.1% | 17.3% |
| Net margin | -70.4% | 6.0% |
| Return on equity | -61.6% | 4.7% |
| P/E ratio | — | 86.6 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 3 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open MRVI — free Open VCEL — freeFrequently asked questions
Which is bigger, MRVI or VCEL?
Vericel Corporation is larger by market capitalization — $1.9B versus $1.9B.
Which grows faster, MRVI or VCEL?
Over the last five fiscal years, Vericel Corporation grew revenue faster — 17.3%/yr versus -8.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.